Press Releases Propanc Biopharma, Inc.

Equities

PPCB

US74346N6022

Market Closed - OTC Markets Other stock markets 01:29:43 11/05/2024 am IST			5-day change	1st Jan Change
0.001 ^USD	0.00%		+25.00%	-91.67%

16/04	Propanc Biopharma, Inc. Receives Certificate of Grant for ?Composition of Proenzymes for Cancer Treatment? Patent from European Patent Office	CI
16/04	Propanc Biopharma, Inc. announced that it has received $0.025 million in funding from GS Capital Partners LLC	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Propanc Biopharma : Material Agreement - Form 8-K	22/04	PU
Propanc Biopharma Receives Certificate of Grant for Composition of Proenzymes for Cancer Treatment Patent from European Patent Office	17/04	AQ
Propanc Biopharma's CEO Shares Views on Revolutionizing Cancer Treatment, an inside Look at Drug Development and Strategic Financing	09/04	AQ
Propanc Biopharma : Material Agreement - Form 8-K	12/03	PU
Propanc Biopharma to Host Corporate Update Call Highlighting Recent Progress and Positive Results from Compassionate Use Study	23/02	AQ
Propanc Biopharma's Joint Research Partner Pushing Boundaries to Circumvent Chemotherapy Resistance Using PRP	14/12	AQ
Propanc Biopharma Peer Reviewed Scientific Article Reaches 3,000 Reads	14/23/14	AQ
Propanc Biopharma : Material Agreement - Form 8-K	12/23/12	PU
Propanc Biopharma Provides Shareholder Update - June 22, 2023	23/23/23	AQ
Propanc Biopharma Provides Shareholder Update	23/23/23	AQ
PROPANC BIOPHARMA, INC. : Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	06/23/06	AQ
Propanc Biopharma Announces That PRP Suppresses TGF- Pathway and Tumor Microenvironment in Pancreatic Cancer	29/23/29	AQ
PROPANC BIOPHARMA, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	18/23/18	AQ
Propanc Biopharma Confirms PRP Exerts Significant Effects against Chemoresistant Pancreatic Tumor Cells	17/23/17	AQ
PROPANC BIOPHARMA, INC. : Other Events (form 8-K)	22/23/22	AQ
PROPANC BIOPHARMA, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits (form 8-K)	22/23/22	AQ
PROPANC BIOPHARMA, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	10/23/10	AQ
Propanc Biopharma's Joint Researcher Receives Award at Doctoral Conference at the University of Jaen	16/22/16	AQ
Propanc Biopharma Concludes PRP Could Become an Effective Chemosensitizer Agent Against Pancreatic Cancer	01/22/01	AQ
Propanc Biopharma's CSO Predicts PRP Could Enhance Therapeutic Effects of Immune Checkpoint Therapy for Pancreatic Cancer	16/22/16	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Propanc Biopharma, Inc.

Equities

PPCB

US74346N6022

Press Releases

Filters